Clinician's Pocket Drug Reference 2008

190 Sorbitolcardiac infarction/ischemia; ↑ pancreatic enzymes, hypophosphatemia, lymphopenia,anemia, fatigue, alopecia, pruritus, D, GI upset, HA, neuropathy Notes: Monitor BPfirst 6 wks; may require ↓ dose (daily or every other day); impaired metabolismw/Asian descent; unknown effect on wound healing, d/c before major surgerySorbitol (generic) Uses: *Constipation* Action: Laxative Dose: 30–60mL PO of a 20–70% soln PRN Caution: [B, +] Contra: Anuria Disp: Liq 70%SE: Edema, electrolyte losses, lactic acidosis, GI upset, xerostomia Notes: May bevehicle for many liq formulations (eg, zinc, Kayexalate)Sotalol (Betapace) WARNING: Monitor pts for 1st 3 d of Rx to ↓ risks ofarrhythmia Uses: *Ventricular arrhythmias, AF* Action: β-adrenergic-blockingagent Dose: Adults. 80 mg PO bid; may be ↑ to 240–320 mg/d Peds. Neonates: 9mg/m 2 tid. 1–19 mo: 20.4 mg/m 2 tid. 20–23 mo: 29.1 mg/m 2 tid; = > 2 y: 30mg/m 2 tid; to max dose of 90 mg/m 2 tid ↓ w/ renal impair Caution: [B (1st tri) (Dif 2nd or 3rd tri), +] Contra: Asthma, COPD, bradycardia, ↑ prolonged QT interval,2nd- or 3rd-degree heart block w/o pacemaker, cardiogenic shock, uncontrolledCHF, CrCl < 40 mL/min Disp: Tabs 80, 120, 160, 240 mg SE: Bradycardia,CP, palpitations, fatigue, dizziness, weakness, dyspnea Notes: Betapace should notbe substituted for Betapace AF because of differences in labelingSotalol (Betapace AF) WARNING: To minimize risk of induced arrhythmia,pts initiated/reinitiated on Betapace AF should be placed for a minimum of3 d (on their maint dose) in a facility that can provide cardiac resuscitation, continuousECG monitoring, & calculations of CrCl; Betapace should not be substitutedfor Betapace AF because of labeling differences Uses: *Maintain sinus rhythmfor symptomatic A fib/flutter* Action: β-adrenergic-blocking agent Dose: Adults.Initial CrCl > 60 mL/min: 80 mg PO q12h. CrCl 40–60 mL/min: 80 mg PO q24h;↑ to 120 mg during hospitalization; monitor QT interval 2–4 h after each dose, w/dose reduction or D/C if QT interval >500 ms. Peds. Neonates: 9 mg/m 2 tid. 1–19mo: 20 mg/m 2 tid. 20–23 mo: 29.1 mg/m 2 tid. = 2 y: 30 mg/m 2 tid; can double alldoses as max daily dose; allow ≈ 36 h between dosage titrations Caution: [B (1sttri; D if 2nd or 3rd tri), +] if converting from previous antiarrhythmic therapy Contra:Asthma, bradycardia, prolonged QT interval, 2nd- or 3rd-degree heart blockw/o pacemaker, cardiogenic shock, uncontrolled CHF, CrCl